1. Incidence of Treatment-Emergent Adverse EventsFrequency and severity of each adverse event; solicited local and systemic AEs from the first vaccination to 12 weeks after first vaccination2. Immunogenicity(1) Change in the neutralizing activity against pseudovirus of SARS-CoV-2 [ID50](2) Change in Geometric mean titer (GMT) of serum anti-SARS-CoV-2 Spike (S) glycoprotein-specific antibody

1. Incidence of Treatment-Emergent Adverse EventsFrequency and severity of each adverse event; solicited local and systemic AEs from the first vaccination to 12 weeks after first vaccination2. Immunogenicity(1) Change in the neutralizing activity against pseudovirus of SARS-CoV-2 [ID50](2) Change in Geometric mean titer (GMT) of serum anti-SARS-CoV-2 Spike (S) glycoprotein-specific antibody